FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Hikma Pharmaceuticals PLC Stock AnalysisComprehensive stock analysis for Hikma Pharmaceuticals PLC (HKMPF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisHKMPF
HKMPF
Hikma Pharmaceuticals PLC
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HKMPF
Home🔹Stocks🔹Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

HKMPF•OTC

Hikma Pharmaceuticals PLC

HKMPF•OTC
Market cap
$4.84B
Sentiment

Your view on HKMPF

Mkt Cap
$4.84B
Sentiment
Your view
HKMPF
Hikma Pharmaceuticals PLC
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
HKMPF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Hikma Pharmaceuticals PLC

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Said Samih Taleb Darwazah
Headquarters
1 New Burlington Place, London, GB
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Said Samih Taleb Darwazah
Headquarters
1 New Burlington Place, London, GB
Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News